Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

• Status: Withdrawn
• Trial end date: 2018-02-06
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Clinically diagnosed autoimmune encephalitis

• Ineffective 1st line treatment (e.g. steroid IV, IVIg) and 2nd line treatment (e.g. Rituximab or cyclophosphamide)

Exclusion Criteria:

• Hemoglobin > 12g/dL

• Hematochrit >36%

• Thrombocytosis > 750K

• AST or ALT > 120

• HIV (+)

• Allergic reaction upon erythropoietin

• Uncontrolled hypertension

• mRS before the autoimmune encephalitis > 3

• Breast feeding or pregnancy

• History of ischemic stroke or pulmonary thrombosis

• Refuse to be enrolled